Skip to Main Content
×
Quiver Logo Get a Free Trial on Quiver Premium Today!
Back to News

Lobbying Update: $70,000 of ALNYLAM PHARMACEUTICALS INC. lobbying was just disclosed

None

$70,000 of ALNYLAM PHARMACEUTICALS INC. lobbying was just disclosed, from Q4 of 2025, in a new Lobbying Disclosure Act filing.

This included lobbying on issues like:

"General Medicare and Medicaid Issues. H.R.1672 - Maintaining Investments in New Innovation (MINI) Act. H.R.946/S.1862 - ORPHAN Cures Act. Pediatric Review Reauthorization."

You can find more data on corporate lobbying on Quiver Quantitative.

ALNY Insider Trading Activity

ALNY Insider Trades

ALNY insiders have traded $ALNY stock on the open market 176 times in the past 6 months. Of those trades, 0 have been purchases and 176 have been sales.

Here’s a breakdown of recent trading of $ALNY stock by insiders over the last 6 months:

  • YVONNE GREENSTREET (Chief Executive Officer) has made 0 purchases and 40 sales selling 41,553 shares for an estimated $18,810,433.
  • DENNIS A AUSIELLO has made 0 purchases and 11 sales selling 31,448 shares for an estimated $13,729,535.
  • COLLEEN F REITAN has made 0 purchases and 16 sales selling 18,000 shares for an estimated $8,416,729.
  • KEVIN JOSEPH FITZGERALD (CSO & EVP, Head of Research) has made 0 purchases and 31 sales selling 15,965 shares for an estimated $7,220,199.
  • MICHAEL W BONNEY sold 11,250 shares for an estimated $5,062,500
  • PUSHKAL GARG (EVP Chief R&D) has made 0 purchases and 31 sales selling 8,810 shares for an estimated $3,991,807.
  • TOLGA TANGULER (EVP, Chief Commercial Officer) has made 0 purchases and 26 sales selling 6,275 shares for an estimated $2,825,534.
  • JEFFREY V. POULTON (EVP, Chief Financial Officer) has made 0 purchases and 20 sales selling 6,095 shares for an estimated $2,758,010.

To track insider transactions, check out Quiver Quantitative's insider trading dashboard.

ALNY Hedge Fund Activity

We have seen 478 institutional investors add shares of ALNY stock to their portfolio, and 287 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

ALNY Analyst Ratings

Wall Street analysts have issued reports on $ALNY in the last several months. We have seen 17 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

  • B of A Securities issued a "Buy" rating on 01/12/2026
  • Needham issued a "Buy" rating on 01/12/2026
  • Truist Securities issued a "Buy" rating on 01/08/2026
  • Stifel issued a "Buy" rating on 12/11/2025
  • Piper Sandler issued a "Overweight" rating on 10/31/2025
  • Barclays issued a "Overweight" rating on 10/31/2025
  • Jefferies issued a "Buy" rating on 10/30/2025

To track analyst ratings and price targets for ALNY, check out Quiver Quantitative's $ALNY forecast page.

ALNY Price Targets

Multiple analysts have issued price targets for $ALNY recently. We have seen 25 analysts offer price targets for $ALNY in the last 6 months, with a median target of $500.0.

Here are some recent targets:

  • Tazeen Ahmad from B of A Securities set a target price of $529.0 on 01/12/2026
  • Joseph Stringer from Needham set a target price of $529.0 on 01/12/2026
  • Danielle Brill from Truist Securities set a target price of $530.0 on 01/08/2026
  • Mani Foroohar from Leerink Partners set a target price of $351.0 on 12/15/2025
  • Paul Matteis from Stifel set a target price of $508.0 on 12/11/2025
  • Derek Archila from Wells Fargo set a target price of $479.0 on 11/11/2025
  • Edward Tenthoff from Piper Sandler set a target price of $489.0 on 10/31/2025

This article is not financial advice. See Quiver Quantitative's disclaimers for more information.

Add Quiver Quantitative to your preferred sources on Google Google News Logo

Suggested Articles